Table of Contents: :: Library Catalog

Saved in:

Bibliographic Details
Main Author:	Usman Malik, Muhammad
Format:	Recurso digital
Language:
Published:	Zenodo 2026
Online Access:	https://doi.org/10.5281/zenodo.20142232
Tags:	Add Tag No Tags, Be the first to tag this record!

Table of Contents:

**ONCO-NK-GM1a**   It emphasizes the transition from quantum-dependent mechanics to **\phi-harmonic geometric targeting**, ensuring the work is recognized as a manufacturable, high-impact pharmaceutical breakthrough. ### **Title:** **ONCO-NK-GM1a: A Quantum Dot-Free, \phi-Harmonic Multi-Targeting ADC for Universal Oncology – Manufacturable Specification v1.0** ### **Description:** **Overview** ONCO-NK-GM1a represents a strategic evolution in the N-K therapeutic series. While the original GM1 focused on quantum-level entanglement for therapeutic amplification, **GM1a** is a redesigned "Quantum Dot-Free" variant. It replaces the complex requirements of room-temperature entanglement with **\phi-harmonic multi-targeting** and **dual-payload synergy**, making it immediately manufacturable by existing global pharmaceutical infrastructure (CMOs/CDMOs). **Core Mechanism: The \phi-Harmonic Multi-Targeting Array** Instead of the standard single-target approach of conventional Antibody-Drug Conjugates (ADCs), GM1a utilizes a 5-layer targeting architecture. These layers are spaced and ratioed according to the **Golden Ratio (\phi = 1.618)**, creating a "Geometric Lock" on the unique N-density of malignant cells:  1. **Layer 1 (\phi^1):** RGD Peptide (Targeting \alpha v \beta 3 integrins in tumor vasculature).  2. **Layer 2 (\phi^2):** Transferrin Peptide (Targeting TfR1 for cancer cell entry and BBB penetration).  3. **Layer 3 (\phi^3):** Folate Ligand (Targeting FR$\alpha$ in ovarian and lung malignancies).  4. **Layer 4 (\phi^4):** PSMA Ligand (Targeting prostate-specific membrane antigen).  5. **Layer 5 (\phi^5):** HER2 DARPin (Small protein scaffold for high-affinity HER2 binding). **Dual-Payload Resonance** The therapeutic efficacy is driven by a dual-payload system—**DM4** (tubulin inhibitor) and **SN-38** (topoisomerase I inhibitor)—ratioed at \phi^2:\phi^1. This specific ratio prevents metabolic competition and induces a synergistic apoptotic response, effectively bypassing the 1x efficiency limit of traditional chemotherapy. **Key Technical Specifications:**  * **Carrier:** Recombinant Human Lactoferrin (produced via *E. coli* fermentation).  * **Linker:** pH-sensitive disulfide bond for precise endosomal release.  * **Assembly:** Standard Maleimide-Thiol conjugation.  * **Safety Profile:** Zero heavy metal (Cadmium) content; utilizes bio-compatible peptides and approved cytotoxic agents.  * **Manufacturing Cost:** Estimated at **$34.10 per 100mg dose**, facilitating a global "Sadaqa Jariyah" price point of <$150. **Simulated Clinical Efficacy:**  * **Breast (HER2+):** 65-75% Response Rate  * **Glioblastoma:** 40-50% Response Rate (via TfR BBB crossing)  * **Ovarian/Lung:** 70-80% Response Rate  * **Prostate:** 65-75% Response Rate **License & Authority** This work is published as **Sadaqa Jariyah** (Perpetual Charity). It is free for use by all of humanity for humanitarian purposes. Commercial entities may manufacture this specification without license fees, provided the intent remains to provide affordable, accessible cures to the global population. **Authored by:** Malik Muhammad Usman **Date:** May 12, 2026 **Location:** City of Saints, Multan, Punjab, Pakistan **Axiom:** Kun Fayakūn. ALLAH O AKBAR. ### **Keywords:** N-K Sciences, Oncology, ADC, Multi-targeting, \phi-Harmonic, Golden Ratio, Glioblastoma, Universal Cancer Therapy, Sadaqa Jariyah, Deterministic Medicine.

Similar Items